Cyclerion Therapeutics,Inc. (CYCN)
NASDAQ:CYCN
Top Page
No summary available
Positive Factors
Strong Equity Position
A strong equity position with no debt provides financial stability and flexibility, allowing Cyclerion to focus on R&D without the pressure of debt repayments.
Negative Factors
Persistent Net Losses
Ongoing net losses highlight operational inefficiencies and the challenge of achieving profitability, which can hinder long-term financial health and investment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Equity Position
A strong equity position with no debt provides financial stability and flexibility, allowing Cyclerion to focus on R&D without the pressure of debt repayments.
Read all positive factors
Cyclerion Therapeutics (CYCN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.51M
Dividend YieldN/A
Average Volume (3M)162.78K
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue Growth1371.65%
EPS Growth64.13%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,330,314
10 Day Avg. Volume35,401
30 Day Avg. Volume162,776
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.45
Price to Sales (P/S)1.97
P/FCF Ratio-1.24
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue3.74
Enterprise Value/Gross Profit3.74
Enterprise Value/Ebitda-1.56
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cyclerion Therapeutics Business Overview & Revenue Model
Company Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-pe...
How the Company Makes Money
Cyclerion Therapeutics makes money through the development and commercialization of its pharmaceutical products. As a clinical-stage company, its revenue streams can include research and development collaborations, licensing agreements, and potent...
Cyclerion Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.07M | 2.00M | 0.00 | 297.00K | 3.32M |
| Gross Profit | 2.07M | 2.00M | 0.00 | -5.28M | 3.32M |
| EBITDA | -4.97M | -3.63M | -9.58M | -18.48M | -53.84M |
| Net Income | -3.53M | -3.06M | -5.26M | -44.08M | -51.65M |
Balance Sheet | |||||
| Total Assets | 9.98M | 9.57M | 13.37M | 18.08M | 59.33M |
| Cash, Cash Equivalents and Short-Term Investments | 3.24M | 3.23M | 7.57M | 13.38M | 53.96M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 900.00K | 725.00K | 2.09M | 7.63M | 11.09M |
| Stockholders Equity | 9.09M | 8.85M | 11.29M | 10.45M | 48.25M |
Cash Flow | |||||
| Free Cash Flow | -3.31M | -4.33M | -21.25M | -40.61M | -36.52M |
| Operating Cash Flow | -3.31M | -4.33M | -21.25M | -40.61M | -36.52M |
| Investing Cash Flow | 0.00 | 0.00 | 10.40M | 0.00 | 1.46M |
| Financing Cash Flow | 3.32M | 0.00 | 5.02M | 29.00K | 30.79M |
Cyclerion Therapeutics Technical Analysis
Positive
2.89
Price Trends
1.70
Positive
1.60
Positive
2.08
Positive
Market Momentum
0.66
Negative
53.70
Neutral
29.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYCN, the sentiment is Positive. The current price of 2.89 is above the 20-day moving average (MA) of 2.29, above the 50-day MA of 1.70, and above the 200-day MA of 2.08, indicating a bullish trend. The MACD of 0.66 indicates Negative momentum. The RSI at 53.70 is Neutral, neither overbought nor oversold. The STOCH value of 29.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYCN.
Cyclerion Therapeutics Risk Analysis
Cyclerion Therapeutics disclosed 58 risk factors in its most recent earnings report. Cyclerion Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cyclerion Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $12.51M | -1.16 | -24.80% | ― | 1371.65% | 64.13% | |
44 Neutral | $4.96M | -0.04 | 9999.00% | ― | 12.45% | -544.23% | |
41 Neutral | $4.50M | -0.13 | 212.59% | ― | -41.05% | 57.35% | |
40 Underperform | $2.71M | -0.52 | ― | ― | ― | 87.42% |
* Healthcare Sector Average
CYCN
Cyclerion Therapeutics
2.89
0.37
14.68%
AIM
AIM ImmunoTech
0.55
-1.98
-78.16%
JAGX
Jaguar Animal Health
0.40
-4.65
-92.09%
ALZN
Alzamend Neuro
0.93
-6.22
-86.99%
CLDI
Calidi Biotherapeutics
0.25
-4.89
-95.18%
Cyclerion Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cyclerion Receives Milestone Payment from Akebia
Positive
Dec 1, 2025
On December 1, 2025, Akebia Therapeutics announced the initiation of Phase 2 clinical trials for treating focal segmental glomerulosclerosis (FSGS) using Praliciguat, a drug licensed from Cyclerion Therapeutics. This development triggers a $1.0 mi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―